The Women's Tennis Association (WTA) has introduced a new requirement that all players competing on the women's circuit must undergo a genetic test to confirm their biological sex. This policy change was disclosed in a recent amendment to the organization’s eligibility guidelines and will take effect on Tuesday.
Under the new rule, each athlete will be asked to submit a one‑time sample for analysis of the SRY gene – the genetic marker that typically determines male sex – and any player who declines to be tested will be subject to disciplinary measures. Historically, the WTA’s approach to transgender participation allowed women who had transitioned to compete, provided they had officially identified as female and could demonstrate that their blood testosterone levels had remained below a specified threshold for a continuous period of two years. That framework was designed to balance inclusivity with competitive fairness.
However, the association noted that, to date, there are no openly transgender women competing on the WTA Tour or at any tier of professional tennis worldwide. In a formal statement, the WTA explained that the updated policy is intended to establish a clear and uniform standard for determining eligibility to enter its tournaments. "Eligibility to participate in WTA events will be verified through a required, one‑time screening for the SRY gene," the statement read.
"The screening process will commence in 2026 and will be conducted with strict confidentiality and data‑privacy safeguards, alongside a comprehensive player‑engagement programme designed to inform and support athletes throughout the transition." The association also emphasized the sensitivity of the issue, pledging to treat all players with respect and dignity while implementing the new rule in a thoughtful manner. "The WTA recognises that this is a sensitive and complex issue and is committed to treating all players with dignity and implementing the policy in a respectful and thoughtful way," the organization added. The decision follows similar moves by other international sporting bodies. In 2025, World Athletics and World Boxing introduced mandatory SRY testing for female competitors, signalling a broader trend toward genetic verification in elite sport.
Those organisations argued that such testing provides an objective, science‑based method to confirm eligibility and helps to protect the integrity of women’s events. Critics of the WTA’s policy have raised concerns about privacy, the potential for discrimination, and the broader implications for transgender athletes. Human‑rights advocates warn that genetic testing could be used to exclude individuals who do not fit traditional binary definitions of sex, and they call for more inclusive solutions that respect both fairness and the rights of all competitors.
The WTA, for its part, asserts that the measure is narrowly targeted at ensuring a level playing field and will be carried out with the highest standards of confidentiality. From a practical standpoint, the testing protocol will involve a simple biological sample—typically a cheek swab or a small blood draw—collected at an approved medical facility. The sample will be analysed for the presence of the SRY gene, which is located on the Y chromosome and is a key determinant of male development.
If the gene is detected, the athlete would be classified as male and thus ineligible for participation in women’s events. Conversely, a negative result would confirm eligibility under the new rule.
The WTA has also outlined a timeline for implementation. While the official start date is set for 2026, the association plans to roll out an extensive communication campaign throughout 2025 to educate players, coaches, and national federations about the testing process, the privacy safeguards in place, and the consequences of non‑compliance.
This outreach will include webinars, written guidelines, and one‑on‑one consultations for athletes who have questions or concerns. In addition to the testing requirement, the WTA reaffirmed its commitment to maintaining a competitive environment that is both fair and welcoming. The association noted that it will continue to monitor scientific research on sex development, hormone regulation, and performance advantages, and it remains open to revisiting its policies as new evidence emerges. The goal, according to the WTA, is to strike a balance between protecting the integrity of women’s tennis and ensuring that all athletes are treated with respect and fairness.
The broader sports community will be watching closely to see how the WTA’s policy is received and whether it sets a precedent for other tennis organisations, including the International Tennis Federation (ITF) and the Association of Tennis Professionals (ATP), which govern the men’s tour. While the ATP has not indicated any intention to adopt similar testing for its events, the conversation about sex verification is likely to continue across multiple disciplines. In summary, the WTA’s new mandate requires a one‑time genetic test for the SRY gene for all female‑category players, with enforcement beginning in 2026.
The policy aims to provide a clear, science‑based eligibility criterion, while the association promises robust privacy protections and a supportive engagement process. As the sports world grapples with the complexities of gender identity, biological sex, and competitive equity, the WTA’s approach represents a significant development that will shape the future of women’s tennis and possibly influence policy decisions in other sports.